The scale of the issue sits inside a much larger cancer burden. The American Cancer Society’s 2026 key statistics for breast cancer estimate about 321,910 new invasive cases and 60,730 new cases of ductal carcinoma in situ in U.S. women this year, while lifetime risk remains about 1 in 8.
Why post-mastectomy pain syndrome is still missed
Despite the name, PMPS is not limited to full breast removal. The American Cancer Society’s overview of post-mastectomy pain syndrome notes that it can also follow breast-conserving surgery, such as lumpectomy. Symptoms can include pain and tingling in the chest wall, armpit and arm, along with shoulder or scar pain, numbness, shooting pain or even severe itching.
That overlap with normal recovery can be part of the problem. Early postsurgical pain is expected. Chronic neuropathic pain months later is not. Risk rises with factors such as axillary lymph node dissection, radiation therapy, younger age, excess body weight, and a history of anxiety or depression, which means some patients enter surgery with a higher chance of long-lasting pain than they may realize.
Post-mastectomy pain syndrome treatment gaps remain wide
Treatment exists, but the evidence base is still uneven. A 2024 review of perioperative interventions to prevent PMPS found that only nine of 23 recent studies reported a significant improvement in incidence and/or severity, and concluded that prevention evidence remains mixed. In practice, that leaves patients reliant on whether a care team quickly recognizes the syndrome and routes them toward rehabilitation, neuropathic-pain treatment, nerve blocks, scar care or other supportive therapies before the pain hardens into disability.
What makes the gap more frustrating is that PMPS is not an obscure complication. It is a known one. Yet patients can still leave surgery knowing about infection, lymphedema and recurrence risk in far greater detail than they know about chronic nerve pain, even though PMPS can directly affect arm function and quality of life.
Older research shows the warnings have been there for years
This blind spot is not new. A 2008 epidemiological study found a PMPS prevalence of 24%. A 2018 review of risk factors and current approaches to treatment further mapped the syndrome’s mechanisms and management challenges. And a 2021 open-access review of treatment outcomes said that, despite growing research on prevention, risk factors and treatment, there was still no cohesive treatment paradigm.
The implication is hard to ignore: the medical literature has been flagging this complication for years, but care may still depend too heavily on early recognition and referral rather than a universal, standardized path.
Post-mastectomy pain syndrome is not rare, not trivial and not simply the price of surviving breast cancer. The next improvement in breast surgery may not be a new device or technique, but a more consistent promise that patients will be warned about chronic pain beforehand, screened for it afterward and treated before it becomes a life-altering condition.
